Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.

Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, Baselga J, Richardson AL, Rodig SJ, D'Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI.

Cell Rep. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077.

2.

RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway.

Xie J, Kim H, Moreau LA, Puhalla S, Garber J, Al Abo M, Takeda S, D'Andrea AD.

J Clin Invest. 2015 Apr;125(4):1523-32. doi: 10.1172/JCI79325. Epub 2015 Mar 9.

3.

Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.

Sawyer SL, Tian L, Kähkönen M, Schwartzentruber J, Kircher M; University of Washington Centre for Mendelian Genomics; FORGE Canada Consortium, Majewski J, Dyment DA, Innes AM, Boycott KM, Moreau LA, Moilanen JS, Greenberg RA.

Cancer Discov. 2015 Feb;5(2):135-42. doi: 10.1158/2159-8290.CD-14-1156. Epub 2014 Dec 3.

4.

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6. doi: 10.1073/pnas.1305170110. Epub 2013 Oct 1.

5.

Inactivation of Uaf1 causes defective homologous recombination and early embryonic lethality in mice.

Park E, Kim JM, Primack B, Weinstock DM, Moreau LA, Parmar K, D'Andrea AD.

Mol Cell Biol. 2013 Nov;33(22):4360-70. doi: 10.1128/MCB.00870-13. Epub 2013 Sep 3.

6.

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.

Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT.

Nat Med. 2012 Jul;18(7):1118-22. doi: 10.1038/nm.2819.

7.

Overcoming reprogramming resistance of Fanconi anemia cells.

Müller LU, Milsom MD, Harris CE, Vyas R, Brumme KM, Parmar K, Moreau LA, Schambach A, Park IH, London WB, Strait K, Schlaeger T, Devine AL, Grassman E, D'Andrea A, Daley GQ, Williams DA.

Blood. 2012 Jun 7;119(23):5449-57. doi: 10.1182/blood-2012-02-408674. Epub 2012 Feb 27.

8.

Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents.

Kee Y, Huang M, Chang S, Moreau LA, Park E, Smith PG, D'Andrea AD.

Mol Cancer Res. 2012 Mar;10(3):369-77. doi: 10.1158/1541-7786.MCR-11-0497. Epub 2012 Jan 4.

9.

Human MutS and FANCM complexes function as redundant DNA damage sensors in the Fanconi Anemia pathway.

Huang M, Kennedy R, Ali AM, Moreau LA, Meetei AR, D'Andrea AD, Chen CC.

DNA Repair (Amst). 2011 Dec 10;10(12):1203-12. doi: 10.1016/j.dnarep.2011.09.006. Epub 2011 Oct 4.

PMID:
21975120
10.

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

Johnson N, Li YC, Walton ZE, Cheng KA, Li D, Rodig SJ, Moreau LA, Unitt C, Bronson RT, Thomas HD, Newell DR, D'Andrea AD, Curtin NJ, Wong KK, Shapiro GI.

Nat Med. 2011 Jun 26;17(7):875-82. doi: 10.1038/nm.2377.

11.

Fanconi anemia-like presentation in an infant with constitutional deletion of 21q including the RUNX1 gene.

Click ES, Cox B, Olson SB, Grompe M, Akkari Y, Moreau LA, Shimamura A, Sternen DL, Liu YJ, Leppig KA, Matthews DC, Parisi MA.

Am J Med Genet A. 2011 Jul;155A(7):1673-9. doi: 10.1002/ajmg.a.34024. Epub 2011 May 27.

PMID:
21626672
12.

Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60.

Sun Y, Jiang X, Xu Y, Ayrapetov MK, Moreau LA, Whetstine JR, Price BD.

Nat Cell Biol. 2009 Nov;11(11):1376-82. doi: 10.1038/ncb1982. Epub 2009 Sep 27.

13.

Emi1 maintains genomic integrity during zebrafish embryogenesis and cooperates with p53 in tumor suppression.

Rhodes J, Amsterdam A, Sanda T, Moreau LA, McKenna K, Heinrichs S, Ganem NJ, Ho KW, Neuberg DS, Johnston A, Ahn Y, Kutok JL, Hromas R, Wray J, Lee C, Murphy C, Radtke I, Downing JR, Fleming MD, MacConaill LE, Amatruda JF, Gutierrez A, Galinsky I, Stone RM, Ross EA, Pellman DS, Kanki JP, Look AT.

Mol Cell Biol. 2009 Nov;29(21):5911-22. doi: 10.1128/MCB.00558-09. Epub 2009 Aug 24.

14.

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.

Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, Larson R, Zhang J, Protopopov A, Chin L, Pandolfi PP, Silverman LB, Hunger SP, Sallan SE, Look AT.

Blood. 2009 Jul 16;114(3):647-50. doi: 10.1182/blood-2009-02-206722. Epub 2009 May 20.

15.

Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability.

McKenna ES, Sansam CG, Cho YJ, Greulich H, Evans JA, Thom CS, Moreau LA, Biegel JA, Pomeroy SL, Roberts CW.

Mol Cell Biol. 2008 Oct;28(20):6223-33. doi: 10.1128/MCB.00658-08. Epub 2008 Aug 18.

16.

RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites.

Sobhian B, Shao G, Lilli DR, Culhane AC, Moreau LA, Xia B, Livingston DM, Greenberg RA.

Science. 2007 May 25;316(5828):1198-202.

17.

Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated.

Kennedy RD, Chen CC, Stuckert P, Archila EM, De la Vega MA, Moreau LA, Shimamura A, D'Andrea AD.

J Clin Invest. 2007 May;117(5):1440-9. Epub 2007 Apr 12.

18.

Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays.

George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, Fox EA, Meyerson M, Diller L, Fortina P, Look AT, Maris JM.

PLoS One. 2007 Feb 28;2(2):e255.

19.

Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.

Moreau LA, McGrady P, London WB, Shimada H, Cohn SL, Maris JM, Diller L, Look AT, George RE.

Clin Cancer Res. 2006 Oct 1;12(19):5693-7.

20.

IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL.

Barata JT, Boussiotis VA, Yunes JA, Ferrando AA, Moreau LA, Veiga JP, Sallan SE, Look AT, Nadler LM, Cardoso AA.

Blood. 2004 Mar 1;103(5):1891-900. Epub 2003 Nov 13.

PMID:
14615384
21.

Interaction of FANCD2 and NBS1 in the DNA damage response.

Nakanishi K, Taniguchi T, Ranganathan V, New HV, Moreau LA, Stotsky M, Mathew CG, Kastan MB, Weaver DT, D'Andrea AD.

Nat Cell Biol. 2002 Dec;4(12):913-20.

PMID:
12447395
22.

A novel diagnostic screen for defects in the Fanconi anemia pathway.

Shimamura A, Montes de Oca R, Svenson JL, Haining N, Moreau LA, Nathan DG, D'Andrea AD.

Blood. 2002 Dec 15;100(13):4649-54. Epub 2002 Aug 29.

PMID:
12393398
23.

Translocation (2;8)(p12;q24) associated with a cryptic t(12;21)(p13;q22) TEL/AML1 gene rearrangement in a child with acute lymphoblastic leukemia.

Loh ML, Samson Y, Motte E, Moreau LA, Dalton V, Waters S, Sallan SE, Gilliland DG.

Cancer Genet Cytogenet. 2000 Oct 15;122(2):79-82.

PMID:
11106815

Supplemental Content

Loading ...
Support Center